Companies press releases
CRANBURY, N.J., Sept. 20, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter and fiscal year end 2017 operating results on Monday, September 25, 2017 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team […]
Sep 12, 2017, 07:30 ET CRANBURY, N.J., Sept. 12, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that Anthony M. Manning, Ph.D. was appointed to Palatin’s Board of Directors on September 7,
CRANBURY, NJ, Sept. 6, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN; “Palatin”) announced today that it has entered into a collaboration and license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”), for exclusive rights to develop and commercialize bremelanotide for female sexual
May 16, 2017, 07:30 ET CRANBURY, N.J., May 16, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2017. Quarter and Recent Highlights Bremelanotide –
May 11, 2017, 07:30 ET CRANBURY, N.J., May 11, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2017 operating results on Tuesday, May 16, 2017 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its
CRANBURY, N.J., March 20, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial
Mar 09, 2017, 15:00 ET CRANBURY, N.J., March 9, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that it will be presenting at the 29th Annual ROTH Conference on Tuesday, March 14, 2017, at 11:00 a.m. Pacific Time. The conference will be held at The Ritz Carlton Laguna Niguel in Dana Point, CA.
Palatin Technologies To Present At The 29th Annual ROTH Conference Read More »
CRANBURY, N.J., Feb. 9, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2016. Recent Highlights Rekynda (bremelanotide) – Under development for Hypoactive Sexual Desire
Will Also Report Second Quarter 2017 Results and Discuss Next Steps in its Development Programs Teleconference and Webcast to be held on February 9, 2017 Feb 03, 2017, 06:00 ET CRANBURY, N.J., Feb. 3, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced the closing of its license agreement with AMAG Pharmaceuticals, Inc. (Nasdaq:
CRANBURY, N.J., Jan. 10, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that after the closing of its licensing agreement with AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) for exclusive North American rights to develop and commercialize Rekynda™ (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, it
